Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?

The therapeutic landscape for patients with non-small cell lung cancer (NSCLC) has dramatically evolved with the development and adoption of immune checkpoint inhibitors (ICI) as front-line therapy. These novel antibodies target the interactions in immunoregulatory pathways, between programmed death...

Descripción completa

Detalles Bibliográficos
Autores principales: Britt, Alec S., Huang, Caitlyn, Huang, Chao H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745068/
https://www.ncbi.nlm.nih.gov/pubmed/36523973
http://dx.doi.org/10.3389/fonc.2022.996554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745068/
https://www.ncbi.nlm.nih.gov/pubmed/36523973
http://dx.doi.org/10.3389/fonc.2022.996554

Ejemplares similares